View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 2, 2020updated 12 Jul 2022 11:56am

CytoDyn seeks approval to trial leronlimab for severe Covid-19

Biotechnology firm CytoDyn has submitted a second clinical trial protocol to the US Food and Drug Administration (FDA) for the use of leronlimab to treat severe illness caused by Covid-19 infection.

Biotechnology firm CytoDyn has submitted a second clinical trial protocol to the US Food and Drug Administration (FDA) for the use of leronlimab to treat severe illness caused by Covid-19 infection.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The second trial will fall under the investigational new drug filing approved by the FDA to perform a Phase II study of the drug in novel coronavirus patients with mild-to-moderate symptoms.

Under an emergency IND, leronlimab was given to ten severely ill patients at a medical centre in New York City, US.

Leronlimab is an investigational humanised IgG4 monoclonal antibody designed to block CCR5, a cellular receptor involved in HIV infection, tumour metastases, and other diseases.

CytoDyn president and CEO Nader Pourhassan said: “Once again, the FDA continues to be very supportive of everyone’s efforts to increase access to leronlimab in order to assess its therapeutic benefits for a broader range of Covid-19 patients.

“With a study in China indicating the mortality rate among Covid-19 patients requiring mechanical ventilator at more than 85%, the world desperately needs a therapy that can help this patient population.”

The company intends to recruit mild-to-moderately ill, as well as severely ill Covid-19 patients under the same IND approved by the US regulatory agency.

CytoDyn designed the new protocol as a double-blinded trial for around 342 severely ill patients. Participants will receive leronlimab for two weeks.

The primary endpoint of the second trial is mortality rate at 14 days.

The first trial will assess the safety and efficacy of leronlimab administered as a weekly subcutaneous injection. The primary outcome measure is clinical improvement based on a change in total symptom score.

Leronlimab obtained the FDA fast track designation to be used as a combination therapy with HAART for HIV patients and to treat metastatic triple-negative breast cancer.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena